The Temel et al. 2010 NEJM randomised trial of early palliative care integration in metastatic non-small-cell lung cancer produced three unexpected findings: patients in the early palliative care arm had better quality of life, received significantly less aggressive care in the final 60 days of life — and lived a median of 2.7 months longer than patients receiving standard oncology care alone (11.6 vs. 8.9 months). The survival advantage has been replicated in subsequent trials across cancer types and represents the strongest evidence that early palliative integration is not a compromise with longevity but a complement to it. The mechanism is understood: patients with better symptom control and psychological support tolerate treatment better, make more considered decisions about additional interventions, and spend less time in late-stage aggressive treatments that produce no benefit while accelerating decline.
The regret data follow from these outcome differences. Tönnies et al.’s 2021 study of 298 bereaved caregivers of cancer patients (Frontiers in Oncology) measured decision regret directly, using the validated Decision Regret Scale for Caregivers. Caregivers whose relative received aggressive end-of-life care — a new chemotherapy regimen started within 30 days of death, a last chemotherapy dose within 14 days, or more than one ICU day in the final month — reported a mean regret score of 43 out of 100, significantly higher than the 33 out of 100 reported by caregivers of patients who were not treated aggressively (Cohen’s d = 0.49). Decision regret is a more direct measure of the construct than the bereavement-distress proxies used in earlier work, because it asks caregivers specifically whether the care decisions were the right ones. The roughly ten-point gap reflects a structural asymmetry: aggressive end-of-life treatment tends to be experienced afterward as “not enough time together” regardless of outcome, while integrated supportive care tends to be remembered as “they were comfortable and present in a way that mattered.”
The action-dominates pattern in this entry reflects a specific population: adults with advanced/metastatic cancer where curative treatment is no longer the goal. The finding has no bearing on early-stage curable cancers, where aggressive treatment is unambiguously appropriate. “Early palliative care” in the Temel/ENABLE tradition is not hospice-only or abandonment of cancer treatment — it is palliative support integrated from diagnosis alongside active oncology. The Dartmouth Atlas of Health Care documents wide geographic variation in end-of-life cancer care intensity across US hospitals with no corresponding survival benefit from higher intensity, suggesting the aggressive end-of-life treatment pattern is a systemic default rather than a personally optimised choice. The clinical evidence now consistently supports offering early palliative integration as a standard component of advanced cancer care, not as an alternative to it.